Why Medicaid-Style Rebates Aren’t Good for Part D Beneficiaries or the Program

Fact Check Friday: The Truth About Negotiation in Medicare Part D

Chart Pack: Value of Personalized Medicine

PhRMA Statement on Senator Warren’s Proposal

01.22.15 | By

Developing innovative, lifesaving medicines for patients is the sole focus of the biopharmaceutical industry. PhRMA member companies invested more than $50 billion in research and development (R&D) in 2013 and over half a trillion dollars since 2000. This represents the vast majority of all biopharmaceutical R&D spending – both private and government – in the United States.

Recognizing the Value of Innovation in HIV/AIDS Therapy

A new white paper from Boston Healthcare Associates takes a closer look at the remarkable advances we’ve made in the treatment of HIV/AIDS. Progress against HIV/AIDS has occurred through a series of incremental gains in knowledge and discovery, transforming what was once considered an acute fatal illness into a manageable chronic condition for those who have access to treatment.

PhRMA Reporter's Handbook 2014

Debunking the Myths of Treating Hepatitis C

11.04.14 | By

A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)

What They Are Saying about the Value of New Innovative Medicines

09.29.14 | By

It’s not every day that a new treatment becomes available that is able to cure 90 percent of the patients. Yet that is exactly what has happened with new and forthcoming medicines to treat hepatitis C.

HIV Aids In this Together

The Value and Cost of Medicine


Subscribe to RSS - Value